Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Number of End-users, Sales Volume & ASP by Product Type The continuous glucose monitoring (CGM) devices market will witness a robust CAGR of 11.5%, valued at $6.83 billion in 2022, destined to appreciate and reach $16.33 billion by 2030, confirms SMR. The market for continuous glucose monitoring devices was led by North America in 2022, with a revenue share of over 35.64%. A CGM is a device used by insulin-dependent diabetics to monitor blood glucose levels continuously. It consists of a small electrode placed beneath the skin, a transmitter that sends readings at regular intervals & a receiver. The enzymatic technology used by currently approved CGMs reacts with glucose molecules in the interstitial fluid to generate an electric current. This electric current is then relayed from a transmitter attached to the sensor to a reader, which displays the data to the patient. CGM has shown benefit to people with diabetes, such as reduced time spent by a patient when he or she is at the stage of hypoglycemia or lower glycated haemoglobin, all because of early detection. Dexcom G6 & Abbott Free-Style Libre are two CGMs permitted for hospital usage. This was done primarily to ensure patient self-testing and the safety of medical personnel. The American Diabetes Association also released several online resources regarding diabetes and the effect of COVID-19 on diabetic patients. Furthermore, the pandemic has increased the necessity to examine the viability of Continuous Glucose Monitors in institutions to constantly monitor diabetic patients. The U.S. FDA published an advice in April 2020 to increase the accessibility of remote-monitoring devices, particularly CGMs, across all healthcare institutions in the U.S. due to the rising demand. Additionally, a lot of medical institutions and industry participants took significant action to meet the unmet needs of diabetic patients who were struggling financially during the pandemic. The American Diabetes Association, Insulin for Life, as well as the Diabetes Disaster Coalition, for instance, teamed together with Abbott in May 2020 to send 25,000 CGM sensors to hospitals throughout the United States. With such a sensor, these devices enable the observation of blood glucose over a range of time intervals, and the readings are relayed through a wireless network. The appropriate readings are then entered into diabetes management software to aid patients in better understanding of their condition. Key Industry Drivers - Rising Prevalence of Diabetes & Shift towards Personalized Medicine The global ubiquity of diabetes is increasing rapidly. According to the IDF, 536 Mn adults have diabetes, and it is forecasted to reach 783 Mn by 2045. As a chronic condition, diabetes requires rigorous glucose monitoring, and diabetes management is a primary driver for the CGM market. CGM technology provides continuous glucose data, enabling timely adjustments to treatment plans and better glycemic control. CGM technology also allows early detection of hyperglycemia and hypoglycemia, promoting early intervention and preventing complications. The rising prevalence of diabetes drives the demand for CGM devices, as it reduces hospitalizations, complications, and costs associated with diabetes management. CGM devices integrate with smartphones, wearable devices, and digital health platforms, offering a user-friendly and advanced solution for diabetes management. According to a study, the personalized medicine market is poised to reach $6 trillion by 2030 with a growing CAGR of 12%. The healthcare industry is increasingly moving towards personalized medicine, where treatments & interventions are tailored to meet individual patients' needs. This exponential growth in personalized medicine is driving the CGM market. CGM devices play a crucial role in this paradigm shift by providing real-time data on glucose fluctuations and patterns. This enables healthcare professionals to customize diabetes management plans based on individual requirements, optimizing treatment outcomes. Restraints - Cost and Affordability One of the primary restraints for CGM devices is their cost. According to Forbes, CGM costs vary from $100 to $300 per month, depending on the brand and pharmacy. It covers sensors and transmitters, with at-home sensors lasting only for 10-14 days. Replacement sensors are required two or three times a month. CGMs have a one-time reader which costs between $60 and $80. CGM systems involve initial device costs, sensor costs for continuous monitoring, and ongoing costs for sensor replacements. Although the cost of CGM devices has decreased over time, still it remains a significant factor limiting their accessibility and affordability, particularly in regions with limited healthcare resources or inadequate insurance coverage. Opportunities - Covid-19 To Positively Impact the Market, Routine Monitoring of Blood Glucose Levels Will Act as An Opportunity for The Market. COVID-19 is expected to benefit the growth of the market for continuous glucose monitoring devices because the virus has been discovered to be detrimental for diabetic individuals. The American Diabetes Association states that there is currently inadequate evidence to determine if people with diabetes are more prone to contract COVID-19 but such people can experience worse outcomes, such as increased rates of major complications. Therefore, continuous glucose monitoring of diabetic patients can help to identify early COVID-19 symptoms and help to determine the best course of treatment. A greater CAGR is anticipated during the projected period for the continuous glucose monitoring system (CGM) segment, due to their ability to routinely monitor the patient's blood glucose level. CGMs are becoming increasingly popular in both developed & developing nations, which is leading to the enormous expansion of this market sector and the use of this technology in different market segments. For instance, a 2021 article by John Wiley & Sons, Inc. noted that CGM systems were proven more effective than SMBG in controlling diabetes because of their simplicity of use, speed of results, and minimally invasive approach. Market Analysis Of Different Segments Covered in the Report Based on Component Integrated Insulin Pumps Sensors Receivers Transmitters Based on Product SMBG Systems (Testing Strips, Blood Glucose Meters, Lancets) CBM Systems (Transmitters, Sensors, Receiver) Based on Demographics Child Population (≤14 years) Adult population (>14 years) Based on Testing Site Alternate Site Testing Fingertip Testing Based on End User ICUs Diagnostics/Clinics Home Healthcare Based on Application, Gestational Diabetes Type 2 Diabetes Type 1 Diabetes Regional Coverage Analysis North America United States Mexico Canada Europe United Kingdom Deutschland France Spain Italy Netherlands Norway Sweden Denmark Finland Rest of Europe Asia-Pacific China Australia Japan South Korea India Rest of Asia-Pacific LAMEA Brazil Venezuela South Africa Argentina Saudi Arab Rest of LAMEA Component Analysis & Insights Based On the Component, the CGM is categorized into Integrated Insulin Pumps, Sensors, Receivers & Transmitters. The sensors segment has the largest revenue share of 39% and is poised to dominate the CGM market for the forecasted period. The sensor comprises of an analyte, bioreceptor, transducer, electronics, and display. The sensor detects glucose using specific enzymes, converts the recognition into a measurable signal, and quantifies the processed signals. The sensors are of different types based on urine, saliva, tear, and sweat. These wide applications of CGM sensors are proliferating the sensor segment's growth. Sensor technologies have evolved to provide more accurate and reliable glucose measurements, longer wear times, improved patient comfort, and reduced interference from external factors. Developing smaller, more sensitive sensors have also enhanced user experience and convenience. Demographics Analysis & Insights Based on Demographics, the continuous glucose monitoring devices market is categorized into child and adult populations. The adult population segment is growing with the fastest CAGR during the forecasted period. Globally, 422 Mn people have diabetes, and only 3.8% of children have diabetes resulting in the adult population dominating the demographic segment. The adult population dominates the Continuous Glucose Monitoring (CGM) segment due to the high prevalence of type 2 diabetes, lifestyle, and metabolic changes, greater healthcare engagement, and treatment intensification and self-management strategies Application Analysis & Insights By Application, the market has been divided into Gestational Diabetes, Type-2 diabetes & Type-1 diabetes. In 2021, the Type-2 diabetes market segment held a disproportionately large portion of the worldwide market share, driven by the prevalence of Type-2 diabetes patients who are insulin-dependent. For instance, the IDF (International Diabetes Federation) forecasted that there were approximately 537 million type-2 diabetics patient worldwide in 2021, with one in ten of the diabetic patient group at risk of developing this disease. In addition, the CGM is expected to be used more frequently in the type 1 diabetes segment due to its clinically demonstrated effectiveness in lowering the risk of hypoglycemia in this population. End-User Analysis & Insights Based on the End Users, the continuous glucose monitoring devices market is categorized into ICUs, Home Healthcare & Diagnostics/Clinics. The Home Healthcare segment dominates the CGM market with a revenue share of 43%. Home healthcare dominates the Continuous Glucose Monitoring (CGM) market due to its convenience, comfort, personalized care, and enhanced quality of life. CGM devices provide real-time glucose readings, enabling informed decisions about diet, medication & physical activity, leading to better glucose control & improved quality of life. As the global population ages, chronic diseases like diabetes become more prevalent, necessitating convenient and efficient healthcare solutions. The dominance of home healthcare among end users is attributed to convenience, personalized care, and cost-effectiveness. Regional Analysis & Insights North America dominated the worldwide market for CGM devices based on region, with a sale percentage of more than 39% in 2020. Due to a well-established healthcare sector in the region, the local market will continue to grow at a consistent CAGR between 2021 to 2030, thereby maintaining its dominance. The regional market is also anticipated and poised to be driven by the increasing obesity cases, effective reimbursement regulations, and expanding public awareness of cutting-edge technologies for diabetes control. Conversely, from 2021 to 2030, APAC is anticipated to experience the quickest growth rate. The Asia-Pacific region is experiencing an increase in diabetic patients compared to other regions globally. India & China have the most diabetic patients across the globe, according to IDF (International Diabetes Federation). Type I & Type II diabetes have become very common due to the rising socioeconomic inequality & the rise in obesity cases. Continuous Glucose Monitoring Devices Market Report Coverage Report Attribute Details Forecast Period 2021 – 2030 Market size value in 2021 USD 6.13 Billion The Revenue forecast in 2030 USD 16.33 Billion Growth rate 11.5% The base year for estimation 2021 Historical data 2017 - 2021 Segments covered Components, Demographics, End-user, Region Regional scope Europe, Asia Pacific, North America, LAMEA Country scope US, Canada, Mexico, Germany, UK, France, Spain, Italy, Netherlands, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, South Korea, Australia, Africa, Brazil, Argentina, Venezuela, Saudi Arabia, South Africa, rest of LAMEA. Key companies profiled GlySens Incorporated, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Dexcom, Inc., Senseonics Holdings, Inc., A. Menarini Diagnostics, Medtronic plc, lifeScan IP Holdings, Echo Therapeutics, Inc., Johnson & Johnson, B Braun Melsungen AG, Terumo Corporation Continuous Glucose Monitoring Devices Market Competitive landscape Analysis Numerous multinational and local businesses are well represented in the market. Most top corporations engage in strategic partnerships, product development, merger & acquisition, & geographical expansion to enhance their market revenue share. For instance, Medtronic announced on November 2020 that the FDA had approved the "InPen," a smart-insulin pen designed for diabetic patients who require multiple daily injections. A Guardian-CGM system that allows for real time access to patient insulin and glucose data is included with the device. The following are the major companies in the market for continuous glucose monitoring devices: GlySens Incorporated Abbott Laboratories F. Hoffmann-La Roche Ltd. Dexcom, Inc. Senseonics Holdings, Inc. A. Menarini Diagnostics LifeScan IP Holdings LLC Medtronic plc Echo Therapeutics, Inc. Johnson & Johnson B Braun Melsungen AG Terumo Corporation Recent Developments On May 2023, The National Institute for Health and Care Excellence (NICE) in the UK approved that children with type 2 diabetes be treated with real-time CGM & intermittently scanned CGM devices. These two technological advancements have been chosen to replace traditional finger prick testing & insulin therapy. According to a research, children can maintain their ideal blood sugar levels using real-time glucose monitoring devices. On May 2023, The first non-invasive, wearable glucose sensor was created by Afon Technology to measure blood sugar levels without piercing the skin. The innovative device from Afon Technology, disguised as a watch, can successfully read a person's blood glucose levels without injecting them into the skin. The gadget will notify users of high and low blood sugar levels and track individual health trends. On February 2023, Dexcom launched G6 CGM system in Singapore. Dexcom partnered with DKSH for distribution of G6 CMG system in Singapore. The non-invasive, wearable device continuously monitor and transmits data by compatible smart devices. Market Leaders Produce a Variety of Devices, Including: Name Feature Key Player The Eclipse 3 Sensor Features: - Long Term Bluetooth Connectivity Use of Low energy Implantable Sensor Clinical Accuracy Differential Measurement Continental Carbon Company Eversense CGM System Feature: - Discreet Alert Glucose Monitoring Patch Long-Term Convenience Peace of mind and accuracy Gentle on skin Accurate Reading Senseonics Holdings, Inc. GlucoMen Day CGM Feature: - Glucose Monitoring Patch Long-Term Convenience Peace of mind and accuracy Gentle on skin A. Menarini Diagnostics Frequently Asked Question About This Report What are the key factors driving the market? Several reasons primarily cause the rising prevalence of diabetes, including rapid urbanization and the rising trend toward a sedentary lifestyle in emerging and developed nations. Moreover, the prevalence of type-1 or insulin-dependent Type-2 diabetic patients has also significantly increased, which has contributed to the rapid global adoption of these systems. How big is the continuous glucose monitoring market? The global continuous glucose monitoring market size was $6.13 billion in 2021 and is expected to reach a value of $16.33 billion by 2030. What is the continuous glucose monitoring market growth? The global continuous glucose monitoring market is expected to grow at a compound annual growth rate (CAGR) of 11.5% from 2021 to 2030 to reach USD 16.33 billion by 2030. Which market sector held the biggest share of continuous glucose monitoring devices? The highest market share for continuous glucose monitoring devices is attributable to the component segment. Sources https://abbott.mediaroom.com/2021-09-28-Real-World-Data-Show-Abbotts-FreeStyle-LibreLink-App-Users-Spend-More-Time-in-Target-Glucose-Range-Compared-to-Reader-Users https://diabetesatlas.org/data/en/world/ https://pubmed.ncbi.nlm.nih.gov/26908931/ https://main.icmr.nic.in/sites/default/files/upload_documents/ICMR_Guidelines_for_Management_of_Type_1_Diabetes.pdf https://diabetestimes.co.uk/afon-technologys https://www.medicaldevice-network.com/news/nice-glucose-monitoring-diabetes-children/ https://www.diabetes.co.uk/diabetes-prevalence.html https://www.sequenex.com/blog/advancements-opportunities-in-continuous-glucose-monitoring/ https://agamatrix.com/blog/glucose-sensors/ https://www.forbes.com/health/body/continuous-glucose-monitor-cost/ https://www.japi.org/r2645454/from-individualized-to-personalized-medicine-in-diabetes-an-expert-overview https://www.cdc.gov/genomics/about/precision_med.htm https://diabetesatlas.org/data/en/world/ https://en.wikipedia.org/wiki/Continuous_glucose_monitor https://www.strategicmarketresearch.com/market-report/continuous-glucose-monitoring-market 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Continuous Glucose Monitoring Devices Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Continuous Glucose Monitoring Devices Market 4.2.1 market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 market, By Product, 2021 - 2030 (USD Million) 4.5 By Application Business Analysis 4.5.1 market, By Application, 2021 - 2030 (USD Million) 4.6 Component Business Analysis 4.6.1 market, By Component, 2021 - 2030 (USD Million) 4.7 End-user Business Analysis 4.7.1 market, By End-user, 2021 - 2030 (USD Million) 4.8 Demographics Analysis 4.8.1 market, By Demographics, 2021 - 2030 (USD Million) 4.9 Testing Site Analysis 4.9.1 market, By Testing Site, 2021 - 2030 (USD Million) 4.10 Value Chain Analysis 4.11 Market Variable Analysis 4.11.1 Market Drivers Analysis 4.11.2 Market Restraints Analysis 4.12 Business Environment Analysis Tool 4.12.1 market PEST analysis 4.12.2 market Porter’s analysis 4.13 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-user Analysis 5.11.1. Trends in End-user (2014-2021) 5.11.2. Trends in End-user (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. SMBG Systems (Testing Strips, Blood Glucose Meters, Lancets) 7.3.1. SMBG Systems (Testing Strips, Blood Glucose Meters, Lancets) market, 2021 - 2030 (USD Million) 7.4. CBM Systems (Transmitters, Services, Receiver) 7.4.1. CBM Systems (Transmitters, Services, Receiver) market, 2021 - 2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Gestational Diabetes 8.3.1. Gestational Diabetes market, 2021 - 2030 (USD Million) 8.4. Type 2 Diabetes 8.4.1. Type 2 Diabetes market, 2021 - 2030 (USD Million) 8.5. Type 1 Diabetes 8.5.1. Type 1 Diabetes market, 2021 - 2030 (USD Million) 9. Market: By Component Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Integrated Insulin Pumps 9.3.1. Integrated Insulin Pumps market, 2021 - 2030 (USD Million) 9.4. Services 9.4.1. Services market, 2021 - 2030 (USD Million) 9.5. Receivers 9.5.1. Receivers market, 2021 - 2030 (USD Million) 9.6. Transmitters 9.6.1. Transmitters market, 2021 - 2030 (USD Million) 10. Market: By End-user Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. ICUs 10.3.1. ICUs market, 2021 - 2030 (USD Million) 10.4. Diagnostics/Clinics 10.4.1. Diagnostics/Clinics market, 2021 - 2030 (USD Million) 10.5. Home Healthcare 10.5.1. Home Healthcare market, 2021 - 2030 (USD Million) 11. Market: By Demographics Segment Analysis 11.1. Introduction 11.2. Sales Volume & Revenue Analysis (2021-2030) 11.3. Child Population (≤14 years) 11.3.1. Child Population (≤14 years) market, 2021 - 2030 (USD Million) 11.4. Adult population (>14 years) 11.4.1. Adult population (>14 years) market, 2021 - 2030 (USD Million) 12. Market: By Testing Site Segment Analysis 12.1. Introduction 12.2. Sales Volume & Revenue Analysis (2021-2030) 12.3. Alternate Site Testing 12.3.1. Alternate Site Testing market, 2021 - 2030 (USD Million) 12.4. Fingertip Testing 12.4.1. Fingertip Testing market, 2021 - 2030 (USD Million) 13. Market: Regional Outlook 13.1 North America 13.1.1. North America market, By Product, 2021 - 2030 (USD Million) 13.1.2. North America market, By Application, 2021 - 2030 (USD Million) 13.1.3. North America market, by End-user, 2021 - 2030 (USD Million) 13.1.4. North America market, by Testing Site, 2021 - 2030 (USD Million) 13.1.5. North America market, by Demographics, 2021 - 2030 (USD Million) 13.1.6. North America market, by Country, 2021 - 2030 (USD Million) 12.1.4.1. U.S. 12.1.4.1.1. U.S. market, By Product, 2021 - 2030 (USD Million) 12.1.4.1.2. U.S. market, By Application, 2021 - 2030 (USD Million) 12.1.4.1.3. U.S. market, by End-user, 2021 - 2030 (USD Million) 12.1.4.1.4. U.S. market, by Testing Site, 2021 - 2030 (USD Million) 12.1.4.1.5. U.S. market, by Demographics, 2021 - 2030 (USD Million) 12.1.4.1.6. U.S. market, by Country, 2021 - 2030 (USD Million) 12.1.4.2. Canada 12.1.4.2.1. Canada market, By Product, 2021 - 2030 (USD Million) 12.1.4.2.2. Canada market, By Application, 2021 - 2030 (USD Million) 12.1.4.2.3. Canada market, by End-user, 2021 - 2030 (USD Million) 12.2. Europe 12.2.1. Europe market, By Product, 2021 - 2030 (USD Million) 12.2.2. Europe market, By Application, 2021 - 2030 (USD Million) 12.2.3. Europe market, by End-user, 2021 - 2030 (USD Million) 12.2.4. Europe market, by Testing Site, 2021 - 2030 (USD Million) 12.2.5. Europe market, by Demographics, 2021 - 2030 (USD Million) 12.2.6. Europe market, by country, 2021 - 2030 (USD Million) 12.2.4.1 U.K. 12.2.4.1.1. U.K. market, By Product, 2021 - 2030 (USD Million) 12.2.4.1.2. U.K. market, By Application, 2021 - 2030 (USD Million) 12.2.4.1.3. U.K. market, by End-user, 2021 - 2030 (USD Million) 12.2.4.2. Germany 12.2.4.2.1. Germany market, By Product, 2021 - 2030 (USD Million) 12.2.4.2.2. Germany market, By Application, 2021 - 2030 (USD Million) 12.2.4.2.3. Germany market, by End-user, 2021 - 2030 (USD Million) 12.2.4.3. France 12.2.4.3.1. France market, By Product, 2021 - 2030 (USD Million) 12.2.4.3.2. France market, By Application, 2021 - 2030 (USD Million) 12.2.4.3.3. France market, by End-user, 2021 - 2030 (USD Million) 12.2.4.4. Rest of Europe 12.2.4.4.1. Rest of Europe market, By Product, 2021 - 2030 (USD Million) 12.2.4.4.2. Rest of Europe market, By Application, 2021 - 2030 (USD Million) 12.2.4.4.3. Rest of Europe market, by End-user, 2021 - 2030 (USD Million) 12.3. Asia Pacific 12.3.1. Asia Pacific market, By Product, 2021 - 2030 (USD Million) 12.3.2. Asia Pacific market, By Application, 2021 - 2030 (USD Million) 12.3.3. Asia Pacific market, by End-user, 2021 - 2030 (USD Million) 12.3.4. Asia Pacific market, by Testing Site, 2021 - 2030 (USD Million) 12.3.5. Asia Pacific market, by Demographics, 2021 - 2030 (USD Million) 12.3.6. Asia Pacific market, by country, 2021 - 2030 (USD Million) 12.3.4.1. China 12.3.4.1.1. China market, By Product, 2021 - 2030 (USD Million) 12.3.4.1.2. China market, By Application, 2021 - 2030 (USD Million) 12.3.4.1.3. China market, by End-user, 2021 - 2030 (USD Million) 12.3.4.2. India 12.3.4.2.1. India market, By Product, 2021 - 2030 (USD Million) 12.3.4.2.2. India market, By Application, 2021 - 2030 (USD Million) 12.3.4.2.3. India market, by End-user, 2021 - 2030 (USD Million) 12.3.4.3. Japan 12.3.4.3.1. Japan market, By Product, 2021 - 2030 (USD Million) 12.3.4.3.2. Japan market, By Application, 2021 - 2030 (USD Million) 12.3.4.3.3. Japan market, by End-user, 2021 - 2030 (USD Million) 12.3.4.4. South Korea 12.3.4.4.1. South Korea market, By Product, 2021 - 2030 (USD Million) 12.3.4.4.2. South Korea market, By Application, 2021 - 2030 (USD Million) 12.3.4.4.3. South Korea market, by End-user, 2021 - 2030 (USD Million) 12.3.4.5. Rest of ASIA PACIFIC 12.3.4.5.1. Rest of ASIA PACIFIC market, By Product, 2021 - 2030 (USD Million) 12.3.4.5.2. Rest of ASIA PACIFIC market, By Application, 2021 - 2030 (USD Million) 12.3.4.5.3. Rest of ASIA PACIFIC market, by End-user, 2021 - 2030 (USD Million) 12.4. Latin America 12.4.1. Latin America market, By Product, 2021 - 2030 (USD Million) 12.4.2. Latin America market, By Application, 2021 - 2030 (USD Million) 12.4.3. Latin America market, by End-user, 2021 - 2030 (USD Million) 12.4.4. Latin America market, by Testing Site, 2021 - 2030 (USD Million) 12.4.5. Latin America market, by Demographics, 2021 - 2030 (USD Million) 12.4.6. Latin America market, by Component, 2021 - 2030 (USD Million) 12.4.7. Latin America market, by country, 2021 - 2030 (USD Million) 12.4.4.1. Brazil 12.4.4.1.1. Brazil market, By Product, 2021 - 2030 (USD Million) 12.4.4.1.2. Brazil market, By Application, 2021 - 2030 (USD Million) 12.4.4.1.3. Brazil market, by End-user, 2021 - 2030 (USD Million) 12.4.4.2. Mexico 12.4.4.2.1. Mexico market, By Product, 2021 - 2030 (USD Million) 12.4.4.2.2. Mexico market, By Application, 2021 - 2030 (USD Million) 12.4.4.2.3. Mexico market, by End-user, 2021 - 2030 (USD Million) 12.4.4.3. Rest of Latin America 12.4.4.3.1. Rest of the Latin America market, By Product, 2021 - 2030 (USD Million) 12.4.4.3.2. Rest of the Latin America market, By Application, 2021 - 2030 (USD Million) 12.4.4.3.3. Rest of the Latin America market, by End-user, 2021 - 2030 (USD Million) 12.5. MEA 12.5.1. MEA market, By Product, 2021 - 2030 (USD Million) 12.5.2. MEA market, By Application, 2021 - 2030 (USD Million) 12.5.3. MEA market, by End-user, 2021 - 2030 (USD Million) 12.5.4. MEA market, by Component, 2021 - 2030 (USD Million) 12.5.4. MEA market, by Testing Site, 2021 - 2030 (USD Million) 12.5.4. MEA market, by region, 2021 - 2030 (USD Million) 13. Competitive Landscape 13.1 GlySens Incorporated 13.1.1. Company overview 13.1.2. Financial performance 13.1.3. Product Portfolio Analysis 13.1.4. Business Strategy & Recent Development 13.2. Abbott Laboratories 13.2.1. Company overview 13.2.2. Financial performance 13.2.3. Product Portfolio Analysis 13.2.4. Business Strategy & Recent Development 13.3. F. HOFFMANN-LA ROCHE LTD. 13.3.1. Company overview 13.3.2. Financial performance 13.3.3. Product Portfolio Analysis 13.3.4. Business Strategy & Recent Development 13.4. Dexcom, Inc. 13.4.1. Company overview 13.4.2. Financial performance 13.4.3. Product Portfolio Analysis 13.4.4. Business Strategy & Recent Development 13.5. Senseonics Holdings, Inc. 13.5.1. Company overview 13.5.2. Financial performance 13.5.3. Product Portfolio Analysis 13.5.4. Business Strategy & Recent Development 13.6. A. Menarini Diagnostics 13.6.1. Company overview 13.6.2. Financial performance 13.6.3. Product Portfolio Analysis 13.6.4. Business Strategy & Recent Development 13.7. LifeScan IP Holdings LLC 13.7.1. Company overview 13.7.2. Financial performance 13.7.3. Product Portfolio Analysis 13.7.4. Business Strategy & Recent Development 13.8. Medtronic plc 13.8.1. Company overview 13.8.2. Financial performance 13.8.3. Product Portfolio Analysis 13.8.4. Business Strategy & Recent Development 13.9. ECHO THERAPEUTICS, INC. 13.9.1. Company overview 13.9.2. Financial performance 13.9.3. Product Portfolio Analysis 13.9.4. Business Strategy & Recent Development 13.10. Johnson & Johnson 13.10.1. Company overview 13.10.2. Financial performance 13.10.3. Product Portfolio Analysis 13.10.4. Business Strategy & Recent Development 13.11. B Braun Melsungen A 13.11.1. Company overview 13.11.2. Financial performance 13.11.3. Product Portfolio Analysis 13.11.4. Business Strategy & Recent Development 13.12. Terumo Corporation 13.12.1. Company overview 13.12.2. Financial performance 13.12.3. Product Portfolio Analysis 13.12.4. Business Strategy & Recent Development List of Tables (70 Tables) TABLE 1. MARKET, By Product, 2021-2030 (USD Million) TABLE 2. MARKET FOR SMBG Systems (Testing Strips, Blood Glucose Meters, Lancets), BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR CBM Systems (Transmitters, Services, Receiver), BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET, By Application, 2021-2030 (USD Million) TABLE 5. MARKET FOR Gestational Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET FOR Type 2 Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 7. MARKET FOR Type 1 Diabetes, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 9. MARKET FOR ICUs, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Diagnostics/Clinics, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET FOR Home Healthcare, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET, By Component, 2021-2030 (USD Million) TABLE 13. MARKET FOR Integrated Insulin Pumps, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Services, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET, By Demographics, 2021-2030 (USD Million) TABLE 16. MARKET FOR Child Population (≤14 years), BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Health Tracking & Insights, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET FOR Adult population (>14 years), BY REGION, 2021-2030 (USD Million) TABLE 19. MARKET, By Testing Site, 2021-2030 (USD Million) TABLE 20. MARKET FOR Alternate Site Testing, BY REGION, 2021-2030 (USD Million) TABLE 21. MARKET FOR Fingertip Testing, BY REGION, 2021-2030 (USD Million) TABLE 22. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 23. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. NORTH AMERICA MARKET, By Product, 2021-2030 (USD Million) TABLE 25. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million) TABLE 26. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 27. NORTH AMERICA MARKET, BY Testing Site, 2021-2030 (USD Million) TABLE 28. NORTH AMERICA MARKET, BY Demographics, 2021-2030 (USD Million) TABLE 29. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 30. EUROPE MARKET, By Product, 2021-2030 (USD Million) TABLE 31. EUROPE MARKET, By Application, 2021-2030 (USD Million) TABLE 32. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 33. EUROPE MARKET, BY Testing Site, 2021-2030 (USD Million) TABLE 34. EUROPE MARKET, BY Demographics, 2021-2030 (USD Million) TABLE 35. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 36. ASIA-PACIFIC MARKET, By Product, 2021-2030 (USD Million) TABLE 37. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million) TABLE 38. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 39. ASIA-PACIFIC MARKET, BY Testing Site, 2021-2030 (USD Million) TABLE 40. ASIA-PACIFIC MARKET, BY Demographics, 2021-2030 (USD Million) TABLE 41. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 42. LAMEA MARKET, By Product, 2021-2030 (USD Million) TABLE 43. LAMEA MARKET, By Component, 2021-2030 (USD Million) TABLE 44. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 45. LAMEA MARKET, BY Testing Site, 2021-2030 (USD Million) TABLE 46. LAMEA MARKET, BY Demographics, 2021-2030 (USD Million) TABLE 47. GlySens Incorporated: COMPANY SNAPSHOT TABLE 48. GlySens Incorporated: OPERATING SEGMENTS TABLE 49. Abbott Laboratories: COMPANY SNAPSHOT TABLE 50. Abbott Laboratories: OPERATING SEGMENTS TABLE 51. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT TABLE 52. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS TABLE 53. Dexcom, Inc.: COMPANY SNAPSHOT TABLE 54. Dexcom, Inc.: OPERATING SEGMENTS TABLE 55. Senseonics Holdings, Inc.: COMPANY SNAPSHOT TABLE 56. Senseonics Holdings, Inc.: OPERATING SEGMENTS TABLE 57. A. Menarini Diagnostics: COMPANY SNAPSHOT TABLE 58. A. Menarini Diagnostics: OPERATING SEGMENTS TABLE 59. LifeScan IP Holdings LLC: COMPANY SNAPSHOT TABLE 60. LifeScan IP Holdings LLC: OPERATING SEGMENTS TABLE 61. Medtronic plc: COMPANY SNAPSHOT TABLE 62. Medtronic plc: OPERATING SEGMENTS TABLE 63. ECHO THERAPEUTICS, INC.: COMPANY SNAPSHOT TABLE 64. ECHO THERAPEUTICS, INC.: OPERATING SEGMENTS TABLE 65. Johnson & Johnson: COMPANY SNAPSHOT TABLE 66. Johnson & Johnson: OPERATING SEGMENTS TABLE 67. B Braun Melsungen A: COMPANY SNAPSHOT TABLE 68. B Braun Melsungen A: OPERATING SEGMENTS TABLE 69. Terumo Corporation: COMPANY SNAPSHOT TABLE 70. Terumo Corporation: OPERATING SEGMENTS List of Figures (26 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 12 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Continuous Glucose Monitoring Market, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Continuous Glucose Monitoring Market, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-user, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Demographics, 2019 vs. 2025 (USD Million) Figure 15 Market Share, By Component, 2019 vs. 2025 (USD Million) Figure 16 Market Share, By Testing Site, 2019 vs. 2025 (USD Million) Figure 17 Geographical Snapshot of the Market Figure 18 Home Healthcare to Witness Higher CAGR in Market for End-user Segment during Forecast Period. Figure 19 Sensors to Witness Higher CAGR in Market for Component Segment during Forecast Period. Figure 20 Adult population (>14 years) to Witness Higher CAGR in Market for Demographics Segment during Forecast Period. Figure 21 Type 2 Diabetes to Witness Higher CAGR in the Market for Application Segment during Forecast Period. Figure 22 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 23 Market: Drivers, Restraints, Opportunities, and Challenges Figure 24 North America: Market Snapshot Figure 25 Asia Pacific: Market Snapshot Figure 26 Vendor Dive: Evaluation Overview